2021-03-31-accounts - Action Duchenne Limited

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

			ADMINISTRATIVE AND STATUTORY DETAILS	ADMINISTRATIVE AND STATUTORY DETAILS
Board of	Trustees		Mark Silverman
			Gary Fegan
			Roger Cockerton (Treasurer)
			Dr Tina Flatau
			Robert Laid
			Simon Dadd
			Victoria Penrice
			Ellen Lambrix
National Director			Florence Boulton
Scientific	Advisory Board		Dame Professor K	Davies —Chair
			Professor M Wood	—Vice Chair
Registered		office	CAN Mezzanine
			49-51 East Road
			Hoxton
			London
			Nl 6AH
Independent		Examiners	Simpson Wreford LLP
			Wellesley House
			Duke ofWellington	Avenue
			Royal Arsenal
			London
			SE186SS
Company	number		04899036
Charity number			1101971
			SC043S52(Scotland)
Solicitors			Morgan Cole
			Bradley Court
			Park Place
			Cardiff
			CF103DR
Banks			Barclays Bank
			PO Box3
			77North Street,
			Keighley
			BD213SA
			The Co-operative Bank Pic
			PO Box250
			Skelmersdale
			N3 6WT

							12mths to	17mths to
							31March	31March
				2021		2021	2021	2020
				Unresticted		Restricted	Total	Total
			Notes	funds		funds	funds	funds
Income and endowments		from:	4
Donations and legacies				217,844		5,000	222,844	391,158
Charitable activities						125,560	125,560	14,285
Other trading activities				128,874			128,874	352,763
Investments					32		32	228
Other - Government grants				17	028		17028
Total income				3~63	778	~130560	~494338	~758434
Expeaditure on:			16
Raising funds:
Cost ofevents and general		fundraising		41,723			41,723	96,531
Charitable activities:
Campaigning and education				16,041			16,041	24,997
Scientific and clincial research
and grants payable				158,255		141,148	299,403	643,779
Improved management	and
medical care				10	694		10694	16665
Total expenditure				~226	713	~141148	~367861	7~81972
Net income/(expenditure)				137,065		(10,588)	126,477	(23,538)
Transfers between funds				~10		10419
Net movement in funds				~126	646	~169	~126477	~23538
Reconciliation offunds
Balance at I April 2020				91	600	21428	113028	136566
Balance at 31March 2021

	Notes	Notes	2021		2020
Fixed assets
Tangible assets			1,920			1,135
Investments			2			2
			1,922			1,137
Current assets
Debtors			51,093	43,867
Cash at bank	and in hand		396747	98374
			447,840	142,241
Current liabilities
Creditors due within one year			166090	30350
Net current	assets		281 750		111891
Total assets	less current liabilities		283,672		113,028
Creditors due more than one year		9	44 167
Net assets		15			11	28
Represented	by:
Restricted funds		13	21,359		21,428
Unrestricted	funds	14	218146		91600

					12mths to	17mths to
					31March	31March
					2021	2020
				Notes	Total	Total
					(12)	(17)
Csshflows from operating	activities:
Net cash (used in)/provided by operating activities				19	299765	~87 110
Cashflows from investing	activities:
Dividends, interest and rents from investments					33	228
Purchase ofequipment					(1,425)
Purchase ofinvestments
Net cash provided by/(used	in) investing activites				I 392	228
Change in cash and cash equivalents in the reporting			period		298,373	(86,882)
Cash and cash equivalents	as at 1 April 2020			20	98374	185256
Cash and cash equivalents	as at 31March	2021		20

Costs to the company were as follows:
	2021	2020
	(12mths)	(17mths)
Gross wages:
- projects	169,635	62,333
- non-projects	20,498	210,045
Staffpension	4,123	5,687
Employer's NI contributions	14315	23 061

Net incomia	g resources	is st	ated after c	harging
					2021	2020
					(12mths)	(17mths)
Independent	examination	snd	accountancy	fees	7,620	8,697
Depreciation					640	378

Investments
			2021	2020
Programme	related investments
Converlible	loan note in Halo Therapeutics	LLC	225,000	225,000
Less:treated	as grant paid 2012		(224999)	(~224 999

Creditors: amounts falling due within one year
	2021	2020
Trade creditors	21,426	7,311
Accruals and deferred income	137,426	20,655
Tax snd social security		47
Bank loan	5,833
Other creditors	I 405	2337

		Fixed	Current	Current	Long-term
		assets	assets	liabilities	liabiTities	Total
		E				E
Restricted funds			21,259			21,259
Unrestricted	funds	1922	426581	~l66 090	~44167	21R246

				2021	2020
					E
				(12mths)	(17mths)
Grant	—The University ofNewcastle			50,000	50,000
Grant	—CSO				9,063
Grant	—UPPMD	membership			1,810
Grant	—University	Hospitals Bristol NHS Foundation			12,260
Grant	—Queen Mary University		London	25,320
Grant	—University	College London			11,285
Grant	—World Duchenne Organisation			912
Grant	—MD UK				25 000

The following payments in res	pe	ct ofresearch	projects have	been committed to	but not prov	ided for in t
accounts:
					2021	2020
				(12mths)		(17mths)
Grant to The Univerisity ofNewcastle						50,000
Grant to Queen Mary University		London				25 320
						75 320
19.ReconciTiation ofnet income	/	(expenditure)	to net cashflow from operating		activities
				2021		2020
				Total		Total
					E	K
				(12mths)		(17mths)
Net surplus/(deficit) for the reportiag period				36,476		(23,538)
Adjustments for:
Depreciation charges					640	378
Dividends, interest and rents from investments					(33)	(228)
(Increase) / decrease in debtors					(7,226)	40,606
Increase / (decrease) in creditors				169908		~104328
Net cash provided by (used in)		operating activites		2	765

			2021	2020
			(12mths)	(17mths)
Cash in hand			396747	98374
Total cash and cash equivalents				~37
21.Commitments under operating	leases
The Charity had annual commitments		under non-cancellable	leases as set out below:
			2021	2020
				E
			(12mths)	(17mths)
Operating leases which expire: within		two to five years		909
22.Loans and overdrafts
			2021	2020
			(12mths)	(17mths)
Bank loans			50000
Payable within one year			5,833
Payable after one year